AI-generated analysis. Always verify with the original filing.
Celcuity Inc. appointed Charles (Chip) R. Romp as a new independent director to its Board of Directors, effective February 11, 2026, increasing the Board size from seven to eight members. Mr. Romp brings over 25 years of pharmaceutical industry experience, including leadership roles at Secura Bio, Seagen, and Genentech, which is expected to provide valuable commercial oncology expertise as the company advances its lead candidate gedatolisib.
Event Type
Disclosure
Mandatory
Variant
8-K
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On February 1
shall not be incorporated into any filing pursuant to the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation langu
Financial Statements and Exhibits. (d) Exhibits 99.1 Press release dated February 12, 2026 104 Cover Page Interactive Data File (embedded within the Inline XBRL
Charles (Chip) R. Romp
Effective: 2026-02-11
Board voted to increase size from seven to eight members and appoint Mr. Romp